Magic mushroom therapy aims to ease cancer Patients' fear of death
NCT ID NCT05398484
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active placebo (niacin) along with psychotherapy. The goal is to see if this approach improves emotional well-being and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Anschutz Medical campus (CU AMC)
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (a psychedelic compound) combined with psychotherapy
What this could lead to
If it works, this could offer a new way to reduce severe anxiety, depression, and fear of death in people with advanced cancer.
What could go wrong
This is an early-to-mid stage trial with only 200 participants. The active placebo (niacin) may not fully blind participants, and psilocybin can cause intense psychological experiences. Results may not apply to all cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.